Belite Bio Inc (BLTE) Quarterly Income Statement

Quarterly · GAAP · USD millions
Access BLTE Annual Income Statement →
Reviewing income statement figures over time helps illustrate how Belite Bio Inc generates earnings and manages operating expenses.
Quarterly Report, GAAP in USD millions
ITEM
(Dec 31 2025)
Q4 2025
0 0 0 (Dec 31 2024)
Revenues
Total Revenue0.00
Costs & Expenses
Gross Profit0.00
Selling, Administration, Marketing38.83
Research and Development Expense45.38
Total operating costs including COS84.21
Operating income / -loss-84.21
Net Interest (-)Expense / Income0.00
Investment Income, Interest-6.64
Other loss / -income0.04
Total costs & expenses77.61
Income & Taxes
Income / -loss before income taxes-77.61
Income taxes expenses / -benefit0.00
Income after income taxes-77.61
Income / -loss from continuing operations-77.61
Net income / -loss-77.61
Income / -loss to shareholder-77.61
EBIT-77.61
EBITD-77.44
EBITDA-77.43
Earnings Per Share
Basic EPS (excl. extra items)-2.31
Basic Net EPS-2.31
Basic shares outstanding (Mill. of Units)33.54
Diluted Net EPS-2.31
Diluted average shares (Mill. of Units)33.54
4 historic quarters locked

Sign in to unlock the full Belite Bio Inc income statement history.

About BLTE Quarterly Income Statement

What this statement shows

This page presents issuer-reported income statement data, detailing revenue, operating costs, expenses, and earnings as disclosed in SEC 10-Q filings and standardized by CSIMarket. The income statement reflects operating performance over a reporting period rather than financial position at a single date.

Revenue and expense treatment

Revenue and expense items are aligned to support period-to-period comparability. Operating and non-operating items, interest, and income taxes are classified based on issuer disclosures and XBRL tagging.

Source & verification

  • Source: SEC 10-Q filings
  • Filed with the SEC: n/a

Income statement figures represent operating results for each reporting period and may be revised in subsequent filings.